메뉴 건너뛰기




Volumn 6, Issue 10, 2011, Pages

Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: A meta-analysis of randomized controlled trials

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; PARATHYROID HORMONE; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

EID: 80054002136     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026267     Document Type: Article
Times cited : (31)

References (38)
  • 1
    • 0027222768 scopus 로고
    • Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis
    • (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94: 646-650.
    • (1993) Am J Med , vol.94 , pp. 646-650
  • 2
    • 22244432201 scopus 로고    scopus 로고
    • Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis
    • Cremers SC, Pillai G, Papapoulos SE, (2005) Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44: 551-570.
    • (2005) Clin Pharmacokinet , vol.44 , pp. 551-570
    • Cremers, S.C.1    Pillai, G.2    Papapoulos, S.E.3
  • 4
    • 0031672980 scopus 로고    scopus 로고
    • Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis
    • Macedo JM, Macedo CR, Elkis H, De Oliveira IR, (1998) Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis. J Clin Pharm Ther 23: 345-352.
    • (1998) J Clin Pharm Ther , vol.23 , pp. 345-352
    • Macedo, J.M.1    Macedo, C.R.2    Elkis, H.3    de Oliveira, I.R.4
  • 5
    • 19544376123 scopus 로고    scopus 로고
    • Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy
    • Miller PD, (2005) Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Ther 27: 361-376.
    • (2005) Clin Ther , vol.27 , pp. 361-376
    • Miller, P.D.1
  • 6
    • 23944461952 scopus 로고    scopus 로고
    • Mechanism of action of bisphosphonates
    • Reszka AA, Rodan GA, (2003) Mechanism of action of bisphosphonates. Curr Osteoporos Rep 1: 45-52.
    • (2003) Curr Osteoporos Rep , vol.1 , pp. 45-52
    • Reszka, A.A.1    Rodan, G.A.2
  • 7
    • 0030842110 scopus 로고    scopus 로고
    • Bisphosphonate effects and the bone remodeling transient
    • Heaney RP, Yates AJ, Santora AC, (1997) Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res 12: 1143-1151.
    • (1997) J Bone Miner Res , vol.12 , pp. 1143-1151
    • Heaney, R.P.1    Yates, A.J.2    Santora, A.C.3
  • 8
    • 51749102927 scopus 로고    scopus 로고
    • Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance
    • Boonen S, Vanderschueren D, Venken K, Milisen K, Delforge M, et al. (2008) Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Intern Med 264: 315-332.
    • (2008) J Intern Med , vol.264 , pp. 315-332
    • Boonen, S.1    Vanderschueren, D.2    Venken, K.3    Milisen, K.4    Delforge, M.5
  • 9
    • 0035837553 scopus 로고    scopus 로고
    • Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
    • Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434-1441.
    • (2001) N Engl J Med , vol.344 , pp. 1434-1441
    • Neer, R.M.1    Arnaud, C.D.2    Zanchetta, J.R.3    Prince, R.4    Gaich, G.A.5
  • 10
    • 0141684971 scopus 로고    scopus 로고
    • The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
    • Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, et al. (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349: 1207-1215.
    • (2003) N Engl J Med , vol.349 , pp. 1207-1215
    • Black, D.M.1    Greenspan, S.L.2    Ensrud, K.E.3    Palermo, L.4    McGowan, J.A.5
  • 11
    • 38449083492 scopus 로고    scopus 로고
    • Full length parathyroid hormone (1-84) in the treatment of osteoporosis in postmenopausal women
    • Jodar-Gimeno E, (2007) Full length parathyroid hormone (1-84) in the treatment of osteoporosis in postmenopausal women. Clin Interv Aging 2: 163-174.
    • (2007) Clin Interv Aging , vol.2 , pp. 163-174
    • Jodar-Gimeno, E.1
  • 12
    • 0345305666 scopus 로고    scopus 로고
    • Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis
    • Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, et al. (2003) Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88: 5212-5220.
    • (2003) J Clin Endocrinol Metab , vol.88 , pp. 5212-5220
    • Hodsman, A.B.1    Hanley, D.A.2    Ettinger, M.P.3    Bolognese, M.A.4    Fox, J.5
  • 14
    • 78650264647 scopus 로고    scopus 로고
    • Use of recombinant human parathyroid hormone(1-84) in patients with postmenopausal osteoporosis: a prospective, open-label, single-arm, multicentre, observational cohort study of the effects of treatment on quality of life and pain-the PROPOSE study
    • Moricke R, Rettig K, Bethke TD, (2011) Use of recombinant human parathyroid hormone(1-84) in patients with postmenopausal osteoporosis: a prospective, open-label, single-arm, multicentre, observational cohort study of the effects of treatment on quality of life and pain-the PROPOSE study. Clin Drug Investig 31: 87-99.
    • (2011) Clin Drug Investig , vol.31 , pp. 87-99
    • Moricke, R.1    Rettig, K.2    Bethke, T.D.3
  • 15
    • 77957063363 scopus 로고    scopus 로고
    • Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis
    • Lyritis GP, Georgoulas T, Zafeiris CP, (2010) Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis. Ann N Y Acad Sci 1205: 277-283.
    • (2010) Ann N Y Acad Sci , vol.1205 , pp. 277-283
    • Lyritis, G.P.1    Georgoulas, T.2    Zafeiris, C.P.3
  • 17
    • 78649680817 scopus 로고    scopus 로고
    • 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
    • Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, et al. (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182: 1864-1873.
    • (2010) CMAJ , vol.182 , pp. 1864-1873
    • Papaioannou, A.1    Morin, S.2    Cheung, A.M.3    Atkinson, S.4    Brown, J.P.5
  • 18
    • 68049137869 scopus 로고    scopus 로고
    • The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
    • Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6: e1000100.
    • (2009) PLoS Med , vol.6
    • Liberati, A.1    Altman, D.G.2    Tetzlaff, J.3    Mulrow, C.4    Gotzsche, P.C.5
  • 19
    • 0029914622 scopus 로고    scopus 로고
    • Assessing the quality of reports of randomized clinical trials: is blinding necessary?
    • Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
    • (1996) Control Clin Trials , vol.17 , pp. 1-12
    • Jadad, A.R.1    Moore, R.A.2    Carroll, D.3    Jenkinson, C.4    Reynolds, D.J.5
  • 20
    • 77951644239 scopus 로고    scopus 로고
    • Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis
    • Finkelstein JS, Wyland JJ, Lee H, Neer RM, (2010) Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 95: 1838-1845.
    • (2010) J Clin Endocrinol Metab , vol.95 , pp. 1838-1845
    • Finkelstein, J.S.1    Wyland, J.J.2    Lee, H.3    Neer, R.M.4
  • 21
    • 43749087111 scopus 로고    scopus 로고
    • Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial
    • Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis GN, et al. (2008) Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial. Int J Clin Pract 62: 919-924.
    • (2008) Int J Clin Pract , vol.62 , pp. 919-924
    • Anastasilakis, A.D.1    Goulis, D.G.2    Polyzos, S.A.3    Gerou, S.4    Koukoulis, G.N.5
  • 22
    • 23744447531 scopus 로고    scopus 로고
    • Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass
    • McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, et al. (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165: 1762-1768.
    • (2005) Arch Intern Med , vol.165 , pp. 1762-1768
    • McClung, M.R.1    San Martin, J.2    Miller, P.D.3    Civitelli, R.4    Bandeira, F.5
  • 23
    • 0141796739 scopus 로고    scopus 로고
    • The effects of parathyroid hormone, alendronate, or both in men with osteoporosis
    • Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, et al. (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349: 1216-1226.
    • (2003) N Engl J Med , vol.349 , pp. 1216-1226
    • Finkelstein, J.S.1    Hayes, A.2    Hunzelman, J.L.3    Wyland, J.J.4    Lee, H.5
  • 24
    • 18644374464 scopus 로고    scopus 로고
    • A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis
    • Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, et al. (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87: 4528-4535.
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 4528-4535
    • Body, J.J.1    Gaich, G.A.2    Scheele, W.H.3    Kulkarni, P.M.4    Miller, P.D.5
  • 25
    • 78649412131 scopus 로고    scopus 로고
    • Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis
    • Cosman F, Eriksen EF, Recknor C, Miller PD, Guanabens N, et al. (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 26: 503-511.
    • (2011) J Bone Miner Res , vol.26 , pp. 503-511
    • Cosman, F.1    Eriksen, E.F.2    Recknor, C.3    Miller, P.D.4    Guanabens, N.5
  • 26
    • 23444435838 scopus 로고    scopus 로고
    • Daily and cyclic parathyroid hormone in women receiving alendronate
    • Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, et al. (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353: 566-575.
    • (2005) N Engl J Med , vol.353 , pp. 566-575
    • Cosman, F.1    Nieves, J.2    Zion, M.3    Woelfert, L.4    Luckey, M.5
  • 27
    • 36148958951 scopus 로고    scopus 로고
    • Teriparatide or alendronate in glucocorticoid-induced osteoporosis
    • Saag KG, Shane E, Boonen S, Marin F, Donley DW, et al. (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357: 2028-2039.
    • (2007) N Engl J Med , vol.357 , pp. 2028-2039
    • Saag, K.G.1    Shane, E.2    Boonen, S.3    Marin, F.4    Donley, D.W.5
  • 28
    • 30144439980 scopus 로고    scopus 로고
    • Reduced risk of back pain following teriparatide treatment: a meta-analysis
    • Nevitt MC, Chen P, Dore RK, Reginster JY, Kiel DP, et al. (2006) Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 17: 273-280.
    • (2006) Osteoporos Int , vol.17 , pp. 273-280
    • Nevitt, M.C.1    Chen, P.2    Dore, R.K.3    Reginster, J.Y.4    Kiel, D.P.5
  • 29
    • 0037214255 scopus 로고    scopus 로고
    • The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis
    • Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, et al. (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18: 9-17.
    • (2003) J Bone Miner Res , vol.18 , pp. 9-17
    • Orwoll, E.S.1    Scheele, W.H.2    Paul, S.3    Adami, S.4    Syversen, U.5
  • 30
    • 33845369453 scopus 로고    scopus 로고
    • Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk-a meta-analysis
    • Vestergaard P, Jorgensen NR, Mosekilde L, Schwarz P, (2007) Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk-a meta-analysis. Osteoporos Int 18: 45-57.
    • (2007) Osteoporos Int , vol.18 , pp. 45-57
    • Vestergaard, P.1    Jorgensen, N.R.2    Mosekilde, L.3    Schwarz, P.4
  • 31
    • 0032767389 scopus 로고    scopus 로고
    • Alendronate increases bone density and bone strength at the distal radius in postmenopausal women
    • Schneider PF, Fischer M, Allolio B, Felsenberg D, Schroder U, et al. (1999) Alendronate increases bone density and bone strength at the distal radius in postmenopausal women. J Bone Miner Res 14: 1387-1393.
    • (1999) J Bone Miner Res , vol.14 , pp. 1387-1393
    • Schneider, P.F.1    Fischer, M.2    Allolio, B.3    Felsenberg, D.4    Schroder, U.5
  • 32
    • 0033042160 scopus 로고    scopus 로고
    • Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits
    • Hirano T, Burr DB, Turner CH, Sato M, Cain RL, et al. (1999) Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 14: 536-545.
    • (1999) J Bone Miner Res , vol.14 , pp. 536-545
    • Hirano, T.1    Burr, D.B.2    Turner, C.H.3    Sato, M.4    Cain, R.L.5
  • 33
    • 0035051721 scopus 로고    scopus 로고
    • Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits
    • Mashiba T, Burr DB, Turner CH, Sato M, Cain RL, et al. (2001) Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits. Bone 28: 538-547.
    • (2001) Bone , vol.28 , pp. 538-547
    • Mashiba, T.1    Burr, D.B.2    Turner, C.H.3    Sato, M.4    Cain, R.L.5
  • 34
    • 77952704223 scopus 로고    scopus 로고
    • The use of PTH in the treatment of osteoporosis
    • Borba VZ, Manas NC, (2010) The use of PTH in the treatment of osteoporosis. Arq Bras Endocrinol Metabol 54: 213-219.
    • (2010) Arq Bras Endocrinol Metabol , vol.54 , pp. 213-219
    • Borba, V.Z.1    Manas, N.C.2
  • 36
    • 0036001310 scopus 로고    scopus 로고
    • Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety
    • Vahle JL, Sato M, Long GG, Young JK, Francis PC, et al. (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30: 312-321.
    • (2002) Toxicol Pathol , vol.30 , pp. 312-321
    • Vahle, J.L.1    Sato, M.2    Long, G.G.3    Young, J.K.4    Francis, P.C.5
  • 37
    • 23444452077 scopus 로고    scopus 로고
    • One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis
    • Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, et al. (2005) One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353: 555-565.
    • (2005) N Engl J Med , vol.353 , pp. 555-565
    • Black, D.M.1    Bilezikian, J.P.2    Ensrud, K.E.3    Greenspan, S.L.4    Palermo, L.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.